Navigation Links
GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM)
Date:10/5/2009

PHILADELPHIA, Oct. 5 /PRNewswire/ -- GlaxoSmithKline [NYSE: GSK] today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.

"Kidney cancer is a very serious disease therefore the committee's recommendation in support of pazopanib is an important step towards bringing a new, oral treatment option to advanced renal cell cancer patients," said Rafael Amado, MD, Vice President, GlaxoSmithKline Oncology R&D Unit. "We look forward to working with the FDA towards the approval of pazopanib."

RCC is the most common type of kidney cancer and accounts for approximately nine out of ten cases. It is estimated that approximately 57,700 people will be diagnosed with kidney cancer and 13,000 people will die from kidney cancer in the United States in 2009. In 2002, an estimated 208,000 new cases of kidney cancer were diagnosed globally.

The advisory committee made its decision based on Phase III pivotal trial data that were presented at the American Society of Clinical Oncology 2009 annual meeting.

About pazopanib

Pazopanib is an investigational medicine that may prevent the growth of new blood vessels to tumors, a process known as angiogenesis. All solid tumors need blood vessels to survive, and medicines in this category may halt the progression of tumor growth.

About pazopanib and clinical development

In its pivotal study, pazopanib was administered orally, once daily. Pazopanib has a broad clinical program across multiple tumor types, with study details available at www.clinicaltrials.gov. More than 2,000 patients have been treated to date in clinical trials.

Pazopanib is not yet approved in any country.

GSK in Oncology

GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in the lives of patients. Through GSK's revolutionary "bench to bedside" approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector. Our worldwide research in oncology includes collaborations with more than 160 cancer centers. GSK is closing in on cancer from all sides with a new generation of patient focused cancer treatments in prevention, supportive care, chemotherapy and targeted therapies.

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

Note to Editors:

VOTRIENT(TM) is the proposed registered trademark to be used in the United States and Europe.

    Enquiries:
    UK Media enquiries:                   Philip Thomson       (020) 8047 5502
                                          Stephen Rea          (020) 8047 5502
                                          Alexandra Harrison   (020) 8047 5502
                                          Gwenan White         (020) 8047 5502
                                          Claire Brough        (020) 8047 5502

    US Media enquiries:                   Nancy Pekarek        (919) 483 2839
                                          Mary Anne Rhyne      (919) 483 2839
                                          Kevin Colgan         (919) 483 2839
                                          Sarah Alspach        (919) 483 2839

    European Analyst/Investor enquiries:  David Mawdsley       (020) 8047 5564
                                          Sally Ferguson       (020) 8047 5543
                                          Gary Davies          (020) 8047 5503

    US Analyst/Investor enquiries:        Tom Curry            (215) 751 5419
                                          Jen Hill Baxter      (215) 751 7002

         Cautionary statement regarding forward-looking statements
         Under the safe harbor provisions of the U.S. Private Securities
         Litigation Reform Act of 1995, GSK cautions investors that any
         forward-looking statements or projections made by GSK, including
         those made in this announcement, are subject to risks and
         uncertainties that may cause actual results to differ materially
         from those projected. Factors that may affect GSK's operations
         are described under 'Risk Factors' in the 'Business Review' in
         the company's Annual Report on Form 20-F for 2008.

         Registered in England & Wales:
         No. 3888792

         Registered Office:
         980 Great West Road
         Brentford, Middlesex
         TW8 9GS


SOURCE GlaxoSmithKline


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
2. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
3. FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmabs ARZERRA(TM) (ofatumumab)
4. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
5. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
6. Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline
7. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
8. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
9. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
10. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
11. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016 Lianluo Smart Limited ... "the Company") which develops, markets and sells medical ... China and international markets, recently ... and Treatment New Progress Forum, co-hosted by the ... Province , Guangdong Provincial People,s Hospital and ...
(Date:12/2/2016)... , December 2, 2016 On ... trading session in red, while the Dow Jones Industrial Average ... the close of US markets, which prompted Stock-callers this morning ... NuVasive Inc. (NASDAQ: NUVA ), Smith & Nephew ... NXTM ), and Cesca Therapeutics Inc. (NASDAQ: ...
(Date:12/2/2016)... , Dec 1, 2016 Research and ... "Drug Delivery in Cancer - Technologies, Markets and Companies" to ... , , ... in management of cancer The market value of drug ... market estimates from 2015-2025 are given according to organs involved and ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, a trusted name in ... trial program for all of the company’s desktop riser products. A simple application ... experience. , FlexiSpot’s unique desktop risers use an advanced dual gas spring hovering ...
(Date:12/2/2016)... ... , ... The annual time frame to change Medicare health and prescription drug ... 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to ... make changes during this period order for their new policy to go into effect ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... With the ... through rehabilitation of an injury, patients must find the one that works for them. ... pain, he created a machine that worked and decided to share it with others. ...
(Date:12/2/2016)... ... 02, 2016 , ... Dr. Raffi Hovsepian, a leading plastic, ... 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The prestigious ... experience, and professional associations. , One the most frequently honored surgeons in ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... edition of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic ... health while maintaining fulfilling lives. “We are prolonging life 6 years in the ...
Breaking Medicine News(10 mins):